Article Archive - Page 48 of 61 - Business Chemistry

How to implement ‘access to medicine’ AND enhance economic performance: business model options for global access

by | Sep 2009

‘Access to medicine’ or ‘global access’ is at the core heart of corporate responsibility for pharmaceutical companies. Corporate responsibility, however, is not restricted to a philanthropic dimension (such as donations), which is often referred to as corporate...

Discussing challenges in the chemical industry for five years

by | Feb 2009

Five interesting years of the “Journal of Business Chemistry” (JoBC) have passed and many more are hopefully lying ahead of us, with the 6th volume currently in your hands. The JoBC is read throughout the world. Even though the `sectorial` focus seems quite narrow –...

The Effects of the Financial Crisis on the Future of the Chemical Industry

by | Feb 2009

The chemical industry is also feeling more and more strongly the effects of the financial crisis and the recession in the important markets of the world. Even so, “horror” scenarios are not appropriate. The marked decrease in the oil price is also having a positive...

Mergers & Acquisitions (M&A) in the Pharmaceutical and Chemical Industries: A Lighthouse in Choppy Waters

by | Feb 2009

After record years in 2006 and 2007 that even topped the peak-year 2000, a cooling down of the international market for Mergers and Acquisitions (M&A) could be observed in 2008: Whilst the global transaction volume in 2007 reached about $ 4,400 bn. (2006: $ 3,600...

Open Source Biopharmaceutical Innovation – A Mode of Entry for Firms in Emerging Markets

by | Feb 2009

The open source model provides a valuable framework for collective knowledge production and dissemination. Mirroring the efforts of the open source community that developed Linux, open biopharmaceutical initiatives are enabling companies to access knowledge-based...

« Older Entries

Next Entries »